GlassScriptPhysician profile
John O Knight
NPI 1386008928
$8,970.46
in general payments reported to CMS, 2019-2025
44 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $2,426 · 2023: $2,056 · 2024: $2,010 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,223.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,209.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,053.69 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $739.28 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $693.94 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $669.53 | 2023-2025 | |
| Abbott Laboratories | $646.12 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $431.67 | 2021-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $398.25 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $233.12 | 2021-2025 | |
| Insulet Corporation | $211.35 | 2022-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $204.38 | 2021-2023 | Steglatro, Segluromet, Steglujan |
| Tandem Diabetes Care, INC. | $184.65 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $171.32 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $135.76 | 2021-2025 | Nexletol |
| Recordati_rare_diseases_inc. | $131.69 | 2022-2025 | Isturisa, Signifor Lar |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $125.83 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Pfizer INC. | $121.75 | 2022-2025 | |
| Abiomed | $120.94 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $120.43 | 2022 | |
| Kyowa Kirin, INC. | $110.69 | 2023-2025 | Crysvita |
| Abbvie INC. | $104.23 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.22 | 2022-2023 | Jardiance, Tradjenta, Synjardy |
| Horizon Therapeutics Plc | $101.13 | 2022-2023 | Tepezza |
| Neurocrine Biosciences, INC. | $97.20 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $89.10 | 2022-2025 | Yorvipath |
| Lifescan, INC. | $86.97 | 2022 | |
| Amryt Pharma Holdings LTD | $75.63 | 2023 | Mycapssa |
| Sequel Med Tech, LLC | $74.03 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $73.59 | 2022-2025 | Recorlev |
| Antares Pharma, INC. | $66.60 | 2025 | Xyosted |
| Astellas Pharma US INC | $53.48 | 2023-2025 | Veozah |
| Ibsa Pharma INC. | $43.94 | 2022-2023 | Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $42.74 | 2023-2024 | Unithroid |
| Becton, Dickinson and Company | $31.83 | 2022 | |
| Acella Pharmaceuticals, LLC | $31.05 | 2024-2025 | NP Thyroid 60 |
| Averitas Pharma INC. | $28.87 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $28.24 | 2024 | Strensiq |
| Eusa Pharma (US) LLC | $21.11 | 2022 | |
| Acerus Pharmaceuticals Corporation | $20.20 | 2022 | |
| Chiesi USA, INC. | $18.66 | 2024 | Mycapssa |
| Embecta Corp. | $18.06 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Glaxosmithkline, LLC. | $17.44 | 2025 | Arexvy, Shingrix |
| Tolmar, INC. | $16.51 | 2024 | |
| Ascensia Diabetes Care US INC. | $14.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.